<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dapsone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00250</strong>&#160; (APRD00345)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00250/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00250/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00250.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00250.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00250.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00250.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00250.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00250">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>1,1'-Sulfonylbis[4-aminobenzene]</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-Diaminodiphenyl sulfone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-Diaminodiphenyl sulphone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-Diaminodiphenylsulfone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-Sulfonylbisbenzeneamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-Sulfonyldianilin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4,4'-sulfonyldianiline</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aczone</td><td>Allergan</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antimalarials">Antimalarials</a></li>
<li><a href="/mesh/folic-acid-antagonists">Folic Acid Antagonists</a></li>
<li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li>
<li><a href="/mesh/leprostatic-agents">Leprostatic Agents</a></li>
<li><a href="/mesh/antimycobacterials">Antimycobacterials</a></li></ul></td></tr><tr><th>CAS number</th><td>80-08-0</td></tr><tr><th>Weight</th><td>Average: 248.301<br>Monoisotopic: 248.061948328</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>MQJKPEGWNLWLTK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[(4-aminobenzene)sulfonyl]aniline</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00250.gif?1265922772">show</a>(9.27 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Anilines</td></tr><tr><th>Direct parent</th><td>Sulfonylanilines</td></tr><tr><th>Alternative parents</th><td>Primary Aromatic Amines; Sulfones; Sulfoxides; Polyamines</td></tr><tr><th>Substituents</th><td>primary aromatic amine; sulfone; sulfonyl; sulfoxide; polyamine; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfonylanilines. These are compounds containing an aniline moiety which bears a sulfonyl group at ring position 4.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment and management of leprosy and dermatitis herpetiformis.</td></tr><tr><th>Pharmacodynamics</th><td>Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.</td></tr><tr><th>Mechanism of action</th><td>Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.</td></tr><tr><th>Absorption</th><td>Bioavailability is 70 to 80% following oral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>70 to 90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, mostly CYP2E1-mediated.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Dapsone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0001075" target="_blank">Myeloperoxidase</a></li>
<li><a href="/biodb/bio_entities/BE0000262" target="_blank">Prostaglandin G/H synthase 2</a></li></ul></td><td><a href="/metabolites/DBMET00301">dapsone hydroxylamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/13">Details</a></td></tr><tr><td>Dapsone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003607" target="_blank">Arylamine N-acetyltransferase 2</a></li></ul></td><td><a href="/metabolites/DBMET00014">N-Acetyldapsone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/14">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00301">dapsone hydroxylamine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01043">Nitroso-dapsone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1052">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01043">Nitroso-dapsone</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01045">Dapsone mercaptal intermediate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1061">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01045">Dapsone mercaptal intermediate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01046">Dapsone GSH conjugate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1062">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Renal</td></tr><tr><th>Half life</th><td>28 hours (range 10-50 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.</td></tr><tr><th>Affected organisms</th><td><ul><li>Mycobacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8476</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9705</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5879</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8699</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9311</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9572</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8739</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7416</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.86</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7175</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8955</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6127</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.556</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5795
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9778
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3635 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9859
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.864
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Jacobus pharmaceutical co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.gallipot.com">Gallipot</a></li>
<li>Jacobus Pharmaceutical Co.</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.tolmar.com">Tolmar Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions. </td></tr><tr><td><a href="/drugs/DB01378">Magnesium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Decreased levels of dapsone</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Decreased levels of dapsone</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>Increased toxicity of both products</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>